29 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
community necessary for commercial success.
Even if our products receive marketing approval, if needed, they may nonetheless fail to gain sufficient … market acceptance by physicians, patients, third-party payors, and others in the medical community. If we do not generate significant product revenues
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.
Even if our … payors, and others in the medical community. If we do not generate significant product revenues, we may not become profitable. The degree of market
424B5
5dvcgk
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
pm8q4 1tvgn3
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
po871p4w8
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
pdi0wdzd az
16 Nov 23
Shelf registration
5:23pm
8-K
EX-10.1
pt3brw6t04wewm ns0w
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-10.4
xmroyiv
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-10.3
qy48t
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
8-K
EX-99.3
05gca dle1ta2
20 Sep 23
Entry into a Material Definitive Agreement
4:52pm
DRS
74b86esrdcm6e
14 Aug 23
Draft registration statement
12:00am
8-K
EX-99.1
e04v mpuskc
1 May 23
Departure of Directors or Certain Officers
3:04pm
DEF 14A
d0c36i 259az
1 May 23
Definitive proxy
2:55pm
PRE 14A
go94cgvyoe8a10
19 Apr 23
Preliminary proxy
9:56pm